Wawruch Martin, Murin Jan, Tesar Tomas, Paduchova Martina, Petrova Miriam, Celovska Denisa, Havelkova Beata, Trnka Michal, Aarnio Emma
Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
Front Pharmacol. 2021 May 19;12:687549. doi: 10.3389/fphar.2021.687549. eCollection 2021.
Antiplatelet therapy needs to be administered life-long in patients with peripheral arterial disease (PAD). Our study was aimed at 1) the analysis of non-persistence with antiplatelet medication in older PAD patients and 2) identification of patient- and medication-related characteristics associated with non-persistence. The study data was retrieved from the database of the General Health Insurance Company. The study cohort of 9,178 patients aged ≥ 65 years and treated with antiplatelet medications was selected from 21,433 patients in whom PAD was newly diagnosed between 01/2012 and 12/2012. Patients with a 6 months treatment gap without antiplatelet medication prescription were classified as non-persistent. Characteristics associated with non-persistence were identified using the Cox regression. At the end of the 5 years follow-up, 3,032 (33.0%) patients were non-persistent. Age, history of ischemic stroke or myocardial infarction, clopidogrel or combination of aspirin with clopidogrel used at the index date, higher co-payment, general practitioner as index prescriber and higher overall number of medications were associated with persistence, whereas female sex, atrial fibrillation, anxiety disorders, bronchial asthma/chronic obstructive pulmonary disease, being a new antiplatelet medication user (therapy initiated in association with PAD diagnosis), and use of anticoagulants or antiarrhythmic agents were associated with non-persistence. In patients with an increased probability of non-persistence, an increased attention should be paid to improvement of persistence.
抗血小板治疗需要在周围动脉疾病(PAD)患者中终身进行。我们的研究旨在:1)分析老年PAD患者抗血小板药物治疗的不持续性;2)确定与不持续性相关的患者及药物相关特征。研究数据取自通用健康保险公司的数据库。从2012年1月至2012年12月新诊断为PAD的21433例患者中,选取了9178例年龄≥65岁且接受抗血小板药物治疗的患者作为研究队列。抗血小板药物处方中断6个月的患者被归类为治疗不持续。使用Cox回归确定与不持续性相关的特征。在5年随访结束时,3032例(33.0%)患者治疗不持续。年龄、缺血性中风或心肌梗死病史、索引日期使用氯吡格雷或阿司匹林与氯吡格雷联合用药、较高的自付费用、索引处方医生为全科医生以及总体用药数量较多与治疗持续相关,而女性、心房颤动、焦虑症、支气管哮喘/慢性阻塞性肺疾病、新使用抗血小板药物(与PAD诊断相关开始治疗)以及使用抗凝剂或抗心律失常药物与治疗不持续相关。对于不持续性可能性增加的患者,应更加关注提高治疗持续性。